Use of CD24 for lowering low-density lipoprotein cholesterol levels
AssigneeOncoimmune, Inc.
InventorsYang Liu, Pan Zheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
Claims16
A method for treating low-density lipoprotein cholesterol (LDL-C)-associated atherosclerosis in a human subject in need thereof, comprising administering to the subject a CD24 protein, wherein the CD24 protein comprises a mature human CD24 polypeptide comprising the sequence set forth in SEQ ID NO:
- 1 or 2, and wherein the mature human CD24 polypeptide is fused at its C-terminus to a Fc region of a human IgG protein.
A method for lowering the risk of LDL-C-associated atherosclerotic cardiovascular disease in a human subject in need thereof, comprising administering to the subject a CD24 protein, wherein the CD24 protein comprises a mature human CD24 polypeptide comprising the sequence set forth in SEQ ID NO:
- 1 or 2, and wherein the mature human CD24 polypeptide is fused at its C-terminus to a Fc region of a human IgG protein.
Dependencies are inferred from the claim text.